COMPANY

AcuraStem

acurastem.com ↗ · Europe

Also known as ACURASTEM INC · 14 sources

Keywords: neurology neurodegenerative diseases

Profile checked Oct 10, 2026

14NIH grants

NIH awards 14

Annual award amounts. Total $12.1M.

Sep 6, 2024 NIH award 5R44NS132698-02 FY2024: $1,279,990 awarded for that fiscal year; activity R44 (SBIR); PI CHANG, WEN-HSUAN; recipient as written: ACURASTEM, INC., Pasadena, CA. Development of an UNC13A antisense oligonucleo source ↗
Aug 28, 2024 NIH award 5R44AG085411-02 FY2024: $1,402,110 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. Development of a SYF2 antisense oligonucleoti source ↗
Aug 28, 2023 NIH award 1R44NS132698-01 FY2023: $1,390,906 awarded for that fiscal year; activity R44 (SBIR); PI SAZANI, PETER; recipient as written: ACURASTEM, INC., Pasadena, CA. Development of an UNC13A antisense oligonucleotid source ↗
Jul 31, 2023 NIH award 1R44AG085411-01 FY2023: $1,492,509 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. Development of a SYF2 antisense oligonucleoti source ↗
Sep 2, 2022 NIH award 3R44NS124454-02S1 FY2022: $76,492 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. Development of a PIKFYVE antisense oligonucleo source ↗
Aug 31, 2022 NIH award 3R44NS124454-01S1 FY2022: $40,846 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. Development of a PIKFYVE Antisense Oligonucleo source ↗
Aug 16, 2022 NIH award 5R44NS124454-02 FY2022: $1,480,550 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. Development of a PIKFYVE antisense oligonucle source ↗
Sep 10, 2021 NIH award 1R44NS124454-01 FY2021: $1,014,266 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. Development of a PIKFYVE antisense oligonucle source ↗
Jun 10, 2021 NIH award 5R44NS105156-05 FY2021: $533,459 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. PIKFYVE antagonism as a therapy for C9ORF72-ALS source ↗
Jun 1, 2020 NIH award 5R44NS105156-04 FY2020: $1,148,751 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. PIKFYVE antagonism as a therapy for C9ORF72-A source ↗
Sep 19, 2019 NIH award 4R44NS105156-03 FY2019: $1,316,216 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. PIKFYVE antagonism as a therapy for C9ORF72-A source ↗
May 9, 2019 NIH award 5R44NS105156-02 FY2019: $265,079 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. PIKFYVE antagonism as a therapy for C9ORF72-ALS source ↗
Apr 26, 2018 NIH award 1R44NS105156-01 FY2018: $433,105 awarded for that fiscal year; activity R44 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. PIKFYVE antagonism as a therapy for C9ORF72-ALS source ↗
Sep 13, 2017 NIH award 1R43AG058325-01 FY2017: $224,935 awarded for that fiscal year; activity R43 (SBIR); PI ALWORTH, SAMUEL V; recipient as written: ACURASTEM, INC., Pasadena, CA. Preserving cellular aspects of aging in patient source ↗

Funding and NIH signals

SEC Form D raise Filed a Form D for an offering of up to $5M, no sales reported yet (filed Jun 22, 2026). SEC Form D 0001745880-26-000001 (Jun 22, 2026)
Evidence (1 event)
- Jun 22, 2026 · SEC Form D 0001745880-26-000001
  Name of Issuer: AcuraStem Inc; CIK: 1745880; Address: Pasadena, CA; Submission type: D; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: Yet to Occur; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Convertible promissory note); Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 0; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals